TW201938580A - Ｈｍｇｎ部分肽及使用其之癌症療法 - Google Patents

Ｈｍｇｎ部分肽及使用其之癌症療法 Download PDF

Info

Publication number
TW201938580A
TW201938580A TW108107562A TW108107562A TW201938580A TW 201938580 A TW201938580 A TW 201938580A TW 108107562 A TW108107562 A TW 108107562A TW 108107562 A TW108107562 A TW 108107562A TW 201938580 A TW201938580 A TW 201938580A
Authority
TW
Taiwan
Prior art keywords
amino acid
peptide
identification number
antibody
sequence
Prior art date
Application number
TW108107562A
Other languages
English (en)
Chinese (zh)
Inventor
松島綱治
上羽悟史
弟子丸俊吾
陳昌佑
橫地祥司
石渡義郎
柴山史朗
Original Assignee
國立大學法人東京大學
日商小野藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人東京大學, 日商小野藥品工業股份有限公司 filed Critical 國立大學法人東京大學
Publication of TW201938580A publication Critical patent/TW201938580A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW108107562A 2018-03-08 2019-03-07 Ｈｍｇｎ部分肽及使用其之癌症療法 TW201938580A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018-041560 2018-03-08
JP2018041560 2018-03-08
JP2019-014105 2019-01-30
JP2019014105 2019-01-30

Publications (1)

Publication Number Publication Date
TW201938580A true TW201938580A (zh) 2019-10-01

Family

ID=67846101

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108107562A TW201938580A (zh) 2018-03-08 2019-03-07 Ｈｍｇｎ部分肽及使用其之癌症療法

Country Status (5)

Country Link
US (2) US11572393B2 (https=)
EP (1) EP3763731A4 (https=)
JP (1) JP7302793B2 (https=)
TW (1) TW201938580A (https=)
WO (1) WO2019172358A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7302793B2 (ja) * 2018-03-08 2023-07-04 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
EP4215214A4 (en) * 2020-09-16 2024-07-03 Osaka University THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE
CN114921443B (zh) * 2022-05-05 2023-07-07 重庆医科大学 肺炎链球菌肽链内切酶o在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
PT2374883T (pt) 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
US20110124564A1 (en) 2009-08-25 2011-05-26 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same
WO2015125652A1 (ja) 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
JP7302793B2 (ja) * 2018-03-08 2023-07-04 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法

Also Published As

Publication number Publication date
JP7302793B2 (ja) 2023-07-04
EP3763731A4 (en) 2021-11-17
EP3763731A1 (en) 2021-01-13
US20230220022A1 (en) 2023-07-13
US20200407408A1 (en) 2020-12-31
WO2019172358A1 (ja) 2019-09-12
JPWO2019172358A1 (ja) 2021-03-11
US11919932B2 (en) 2024-03-05
US11572393B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
AU2016269145C1 (en) Therapeutic combinations and methods for treating neoplasia
US11168137B2 (en) Method for reducing side effects of immune checkpoint control agent
CN106999594B (zh) 用于治疗瘤形成的治疗组合
JP2023085370A (ja) 免疫調節剤を併用するがんの治療
US11919932B2 (en) HMGN partial peptide and cancer therapy using the same
EP3132802B1 (en) Therapeutic agent for solid cancer
RS55181B1 (sr) Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea
CN113825527A (zh) 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
CN111094346A (zh) 用于肿瘤特异性细胞消耗的化合物和方法
JP2021511372A (ja) Ｔｉｍ３に対する抗体で癌を処置する方法
WO2018047917A1 (ja) Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
TWI887285B (zh) 抗ｇａｒｐ抗體與免疫調節劑之組合及其用途
CN117355331A (zh) 抗Siglec组合物及其用途
KR20230056761A (ko) Pd-1 저해제의 투여에 의한 암 치료 방법
HK40070578A (en) Combination of anti-garp antibody and immunoregulator
CA3255411A1 (en) COMBINATION OF MULTISPECIFIC MOLECULES AND AN IMMUNE CHECKPOINT INHIBITOR
CN121668303A (zh) 抗pd-1抗体在联合用药中的应用
HK40018012A (en) Compounds and methods for tumour-specific cell depletion
TW201729827A (zh) 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合